新型口服抗凝药与华法林在生物主动脉瓣置换术后早期后房颤中的比较
这项回顾性真实世界研究汇总5中心1032例生物主动脉瓣置换术后至少4个月发生房颤的患者,比较新型口服抗凝药(NOACs)与华法林的疗效与安全性。结果显示NOACs组栓塞/缺血事件和大出血发生率均低于华法林组,倾向评分匹配后结论一致。
要点
- 生物主动脉瓣置换术后4个月以上房颤患者,NOACs较华法林降低栓塞/缺血事件。
- NOACs较华法林降低大出血事件,匹配后结果一致。
- 真实世界数据支持NOACs在该人群中的使用,但需注意回顾性设计局限。
核心结论
- 生物主动脉瓣置换术后发生房颤的患者使用NOACs较华法林更有效预防血栓栓塞且减少大出血事件。
研究设计与样本
- 回顾性真实世界研究,汇总5个中心数据库共1032例患者,其中340例使用NOACs、692例使用华法林,并进行倾向评分匹配。
主要发现
- NOACs组与华法林组栓塞/缺血事件率分别为13.5%(46/340)与22.7%(157/692),HR 0.5(95%CI 0.37-0.75),P<.001。
- NOACs组与华法林组大出血率分别为7.3%(25/340)与13%(90/692),HR 0.5(95%CI 0.33-0.84),P=.007。
- 倾向评分匹配后,NOACs组与华法林组栓塞/缺血事件率分别为13.1%(42/321)与21.8%(70/321),HR 0.6(95%CI 0.4-0.9),P=.02。
- 倾向评分匹配后,NOACs组与华法林组大出血率分别为7.8%(25/321)与13.7%(44/321),HR 0.5(95%CI 0.31-0.86),P=.01。
临床怎么用
- 对于生物主动脉瓣置换术后至少4个月发生房颤的患者,可考虑使用NOACs替代华法林以降低栓塞和大出血风险。
局限性
- 回顾性真实世界研究可能存在未测量混杂,结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of novel nonvitamin K antagonist oral anticoagulants (NOACs) in nonvalvular atrial fibrillation (AF) to prevent stroke is well assessed, but NOACs use in AF that occurs after bioprosthetic aortic valve replacement (AVR) is not endorsed. This retrospective real-world study evaluated the efficacy and safety of NOACs prescribed no earlier than 4 months after AVR as an alternative to warfarin in patients with AF. METHODS: We pooled 1032 patients from the databases of 5 centers. Ischemic/embolic events and major bleeding rates were compared between 340 patients assuming NOACs and 692 prescribed warfarin. Propensity score matching was performed to avoid the bias between groups. RESULTS: The NOACs vs warfarin embolic/ischemic rate was 13.5% (46 of 340) vs 22.7% (157 of 692), respectively, (hazard ratio [HR], 0.5; 95% confidence interval [CI], 0.37-0.75; P < .001), and the incidence rate was 3.7% vs 6.9% patients/year, respectively (log-rank test P = .009). The major bleeding rate was 7.3% (25 of 340) vs 13% (90 of 692) (HR, 0.5; 95% CI, 0.33-0.84; P = .007), and the incidence rate was 2% vs 4% patients/year (log-rank test P = .002.) After propensity score matching, the NOACs vs warfarin embolic/ischemic rate was 13.1% (42 of 321) vs 21.8% (70 of 321) (HR, 0.6; 95% CI, 0.4-0.9; P = .02), and the incidence rate was 4.1% vs 6.7% patients/year (log rank test P = .01). The major bleeding rate was 7.8% (25 of /321) vs 13.7% (44 of 321) (HR, 0.5; 95% CI, 0.31-0.86; P = .01), and the incidence rate was 2.4% vs 4.2% patients/year (log-rank P = .01). CONCLUSIONS: In a real-word study, NOACs use overcomes the indications provided by guidelines. This study evidenced that NOACs use in patients who developed AF after bioprosthetic AVR was more effective in prevention of thromboembolism and safe in reduction of major bleeding events compared with warfarin.
引用
- Mannacio VA, Mannacio L, Antignano A, et al. New Oral Anticoagulants Versus Warfarin in Atrial Fibrillation After Early Postoperative Period in Patients With Bioprosthetic Aortic Valve. Ann Thorac Surg. 2021. PMID: 33744222. doi:10.1016/j.athoracsur.2021.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。